2015
DOI: 10.18632/oncotarget.6658
|View full text |Cite
|
Sign up to set email alerts
|

Novel strategies to target the ubiquitin proteasome system in multiple myeloma

Abstract: Multiple myeloma (MM) is a hematological malignancy characterized by the accumulation of plasma cells in the bone marrow (BM). The success of the proteasome inhibitor bortezomib in the treatment of MM highlights the importance of the ubiquitin proteasome system (UPS) in this particular cancer. Despite the prolonged survival of MM patients, a significant amount of patients relapse or become resistant to therapy. This underlines the importance of the development and investigation of novel targets to improve MM t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
56
0
3

Year Published

2016
2016
2024
2024

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 70 publications
(60 citation statements)
references
References 145 publications
0
56
0
3
Order By: Relevance
“…Bortezomib is a proteasome inhibitor that is FDAapproved for the treatment of multiple myeloma [117,118]. In the medical literature, patients with multiple myeloma and PH can experience reversal of PH symptoms with bortezomib treatment, although adverse pulmonary effects have also been reported in association with this drug [25, 64-71, 73, 75, 76].…”
Section: Discussionmentioning
confidence: 99%
“…Bortezomib is a proteasome inhibitor that is FDAapproved for the treatment of multiple myeloma [117,118]. In the medical literature, patients with multiple myeloma and PH can experience reversal of PH symptoms with bortezomib treatment, although adverse pulmonary effects have also been reported in association with this drug [25, 64-71, 73, 75, 76].…”
Section: Discussionmentioning
confidence: 99%
“…Протеасома обладает тремя основными протеолитическими активностями: химотрипсинподобной (ХПА), трипсинподобной и каспазаподобной (КПА). В клетке протеасомы осуществляют протеолиз цитозольных, ядерных белков, превращение неактивных белков-предшественников в активные, участвуют в образовании регуляторных пептидов [14].…”
Section: оригинальные статьиunclassified
“…Blocking of ERAD in some cancers, such as multiple myeloma, is utilized in the clinic with some success; the FDA approved bortezomib in 2003 for this purpose [39, 40]. However, the use of drugs that inhibit ERAD are limited due to off target toxic effects [41]. Exacerbating ER stress is an attractive alternative.…”
Section: Introductionmentioning
confidence: 99%